A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults

Taejoon Pharmaceutical

Status and phase: Unknown; Phase 1

Conditions: Healthy

Treatments: Other: Placebo (vehicle); Drug: CTO0101

Study type: Interventional

Funder types: Industry

Identifiers

NCT05262179

CTO0101

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristic of CTO0101

Enrollment: 16 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male and female volunteers
• Written informed consent to participate in the trial

Exclusion criteria

• Those who have a history of ophthalmic diseases and surgery within 5 years
• Smokers with an average daily smoking amount exceeding 10 cigarettes

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

16 participants in 2 patient groups, including a placebo group

CTO0101

Experimental group

Treatment:

Drug: CTO0101

Placebo (Vehicle)

Placebo Comparator group

Treatment:

Other: Placebo (vehicle)